about
Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS PhenotypeDual effect of oxidative stress on leukemia cancer induction and treatmentIron chelation therapy in myelodysplastic syndromes: where do we stand?Iron overload induces apoptosis of murine preosteoblast cells via ROS and inhibition of AKT pathway.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Mitoquinone restores platelet production in irradiation-induced thrombocytopenia.Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.S-glutathionylated serine proteinase inhibitors as plasma biomarkers in assessing response to redox-modulating drugsAutophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia.Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia.HFE gene mutation and oxidative damage biomarkers in patients with myelodysplastic syndromes and its relation to transfusional iron overload: an observational cross-sectional studyMouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotypeImportant genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.Myelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications.Reactive oxygen species in eradicating acute myeloid leukemic stem cellsPlasma levels of aminothiols, nitrite, nitrate, and malondialdehyde in myelodysplastic syndromes in the context of clinical outcomes and as a consequence of iron overload.High expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndromeMyelodysplastic syndromes: clinical practice guidelines in oncology.Oxidases and reactive oxygen species during hematopoiesis: a focus on megakaryocytes.Nuclear Nox4-derived reactive oxygen species in myelodysplastic syndromesAn increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells.Intracellular reactive oxygen species mark and influence the megakaryocyte-erythrocyte progenitor fate of common myeloid progenitors.Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome.Selenium compounds induced ROS-dependent apoptosis in myelodysplasia cells.FLT3-driven redox-modulation of Ezrin regulates leukaemic cell migration.Dietary phenolic acids act as effective antioxidants in membrane models and in cultured cells, exhibiting proapoptotic effects in leukaemia cellsHemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome.Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.Alterations in the Reactive Oxygen Species in Peripheral Blood of Chronic Myeloid Leukaemia Patients from Northern India.Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome.Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: A pilot study.Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients.Labile plasma iron, more practical and more sensitive to iron overload in myelodysplastic syndromes.
P2860
Q26744481-2E90C1B1-65AC-4A02-9425-7B81731277EAQ26866544-5A347AEA-515C-4546-99F3-074BE2BA8456Q27011747-E2A6E383-17B4-4CF0-A5B4-3028C0D409B8Q32181246-AAD1CC5B-06B0-45F9-A929-4F978C96A61FQ33393647-F34E0CB1-376A-46D1-8A95-590BC7F0DFDFQ33416435-BCDF3751-090E-43D5-ABEB-B5507FE7261FQ33903052-828E1719-356D-4AC5-881E-C2DCFB0BA2E4Q34117297-44D3C83E-E052-40BA-B866-28D519EABDF5Q35124582-AC18ABC6-7834-4831-82AB-22B923BC5C1BQ35174357-A5D9FC79-FED7-4FDD-9659-DDB2D335A97AQ35332467-0BBF9EA2-C254-47BD-993F-2DD0B9FEC0A7Q36286847-0E37C0FB-FCA9-4335-AF85-4E37D34EC02FQ36417421-525AA8F4-B3A9-4B4F-86A4-6640B91EE84DQ36961721-C3193F76-360C-404A-BF40-2446F3F35229Q37043785-1DE579C2-14B1-4E11-857F-6898E32E8A98Q37616639-D3C3C93B-E67D-43DD-91E3-255FA88BF4AFQ37666492-863A5634-39B6-4FB7-BDEB-C505C7D33734Q37723847-189A77A9-D68E-4DFA-923A-5F8A344D2EB3Q37983798-7EE83A05-D1FA-44EF-BD51-357515C3D647Q38285652-CCAA5F66-3221-4B4D-B9E1-DA7DCD439F98Q38368123-5012E604-FCC3-4066-BBD6-E13784A8D82AQ38713053-DB3D1241-8A3E-4323-B5A4-9D4901141AB5Q39069253-23FD5B93-8D7A-4A46-9A1E-3238F32C4E9FQ39108341-DA6CC60A-C6E3-47DE-A615-C4D7F2CF2956Q39117707-413C93C9-F875-441D-9F9C-86503F77DABDQ39272171-9CB87881-67DC-4B93-9E52-427FCF06FE22Q39315093-C464FA44-93A4-41FB-9649-76DE5823A6B9Q40800759-2BE9671C-C3E7-4C0F-B8CB-E48F6D958D76Q41323380-927A69CB-478E-4284-89FE-CBC28A6C9A4EQ42367100-D79222A4-A068-420A-BB3D-6C771224CACFQ42589425-7033E524-4FE8-4510-8825-583F0B22E8B1Q43667169-57F045E3-5845-43B5-A8AC-43311D83C0B3Q46729480-9DEA7BBE-FFA1-4A30-822D-8DBE8785AC83Q48186090-B5EBFFBB-4EA2-4B97-87F2-C92B7740A9F1Q51790001-1346B400-A311-4C5F-B953-DA886629D134
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Oxidative stress and the myelodysplastic syndromes.
@ast
Oxidative stress and the myelodysplastic syndromes.
@en
type
label
Oxidative stress and the myelodysplastic syndromes.
@ast
Oxidative stress and the myelodysplastic syndromes.
@en
prefLabel
Oxidative stress and the myelodysplastic syndromes.
@ast
Oxidative stress and the myelodysplastic syndromes.
@en
P2860
P356
P1476
Oxidative stress and the myelodysplastic syndromes.
@en
P2093
David T Bowen
Morag J Farquhar
P2860
P2888
P304
P356
10.1007/BF02982641
P577
2003-05-01T00:00:00Z